Office Action Predictor
Application No. 17/420,476

QUANTITATIVE AMPLICON SEQUENCING FOR MULTIPLEXED COPY NUMBER VARIATION DETECTION AND ALLELE RATIO QUANTITATION

Final Rejection §112
Filed
Jul 02, 2021
Examiner
HORTH, LISA ANNE
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
William Marsh Rice University
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
3y 1m
To Grant
51%
With Interview

Examiner Intelligence

66%
Career Allow Rate
21 granted / 32 resolved
Without
With
+-14.8%
Interview Lift
avg trend
3y 1m
Avg Prosecution
34 pending
66
Total Applications
career history

Statute-Specific Performance

§101
10.0%
-30.0% vs TC avg
§103
27.9%
-12.1% vs TC avg
§102
13.6%
-26.4% vs TC avg
§112
46.2%
+6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status This action is written in response to applicant’s correspondence received 8/7/2025. Claims 1, 3-5,9,17,22,24-26,41,43,47,52 are currently pending and under examination, claims 27, 29,34-36 and 40 are withdrawn and claims 2,6-8,10-16,18-21,23,28,30-33,37-39,42,44-46,48-51,53-57 are cancelled. Response to Remarks: The 35 USC § 112(b) and §103 rejections are withdrawn in view of amendments. Specification Objection The disclosure is objected to because of the following informalities: The use of the terms MiSeq and SoLiD, are trade name or marks used in commerce, and have been noted in this application, at least at [0099], [0032] [0034] and at [0088], [0092] respectively. The terms should be accompanied by the generic terminology; furthermore the term should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM, or ® following the term. Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3-5, 9, 17, 22, 24-26, 41,43,47, and 52 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is indefinite over the recitation of the following phrase: the resulting amplicons are “suitable for qNGS to enable detection of CNV and allele ratio quantitation”. It is unclear what is intended exactly by suitable for qNGS and whether this is meant to reference overall quality of sample, or amplicon length, or quantity, or number of variants for a given site going to be sequenced, or something different, particularly since the phrase continues: to enable detection of CNV and allele ratio quantitation. Further, allele ratio quantitation is something that is performed. There is no definitions section for interpretation of this terminology in this context. ‘Suitable’ appears once in the specification [0096] unrelated to this statement, and ‘suitably’ appears once [0097], unrelated and no other similar recitations exist. The meaning is ambiguous at present. Claims 3-5, 9, 17, 22, 24-26, 41,43,47,52 depend from claim 1 and are indefinite for the same reason. Claim 1 also recites the limitation "the resulting amplicons". There is insufficient antecedent basis for this limitation in the claim. Claims 3-5, 9, 17, 22, 24-26, 41,43,47,52 depend from claim 1 and are indefinite for the same reason. Conclusion All claims are rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa Horth whose telephone number is (703)756-4557. The examiner can normally be reached Monday-Friday 8-4 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LISA HORTH/Examiner, Art Unit 1681 /GARY BENZION/Supervisory Patent Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Jul 02, 2021
Application Filed
May 02, 2025
Non-Final Rejection — §112
Aug 07, 2025
Response Filed
Dec 05, 2025
Final Rejection — §112
Mar 30, 2026
Request for Continued Examination
Apr 01, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology. Study what changed to get past this examiner.

Patent 12571032
POLYMERASE-TEMPLATE COMPLEXES
2y 5m to grant Granted Mar 10, 2026
Patent 12559785
Analyte Enrichment Methods and Compositions
2y 5m to grant Granted Feb 24, 2026
Patent 12559794
METHOD FOR NUCLEIC ACID AMPLIFICATION
2y 5m to grant Granted Feb 24, 2026
Patent 12534766
RAPID DETECTION OF ANTIMICROBIAL RESISTANCE BY MICROBIAL RIBOSOME IMMUNOPRECIPITATION
2y 5m to grant Granted Jan 27, 2026
Patent 12517111
SYSTEMS AND METHODS FOR IDENTIFYING AND ISOLATING INVASIVE SUBPOPULATIONS OF CANCER CELLS IN REAL-TIME
2y 5m to grant Granted Jan 06, 2026

AI Strategy Recommendation

Click below to generate an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
51%
With Interview (-14.8%)
3y 1m
Median Time to Grant
Moderate
PTA Risk
Based on 32 resolved cases by this examiner